5 Biotechnology stocks are moving up in their overall rating this week, according to the Portfolio Grader database. Every one of these is graded an “A” (“strong buy”) or “B” overall (“buy”).

This week, Cellectis SA Sponsored ADR’s (CLLS) ratings are up from a C last week to a B. The company also gets A’s in sales growth and earnings revisions. For more information, get Portfolio Grader’s complete analysis of CLLS stock.

This is a strong week for Genomic Health, Inc. (GHDX). The company’s rating climbs to B from the previous week’s C. Genomic Health, Inc. is a life science company, which is focused on the development and commercialization of genomic-based clinical diagnostic tests for cancer that allow physicians and patients to make individualized treatment decisions. The company also gets A’s in earnings momentum. For more information, get Portfolio Grader’s complete analysis of GHDX stock.

The rating of Loxo Oncology Inc (LOXO) moves up this week, rising from a B to a A. The company also gets A’s in earnings revisions. For more information, get Portfolio Grader’s complete analysis of LOXO stock.

Coherus BioSciences, Inc. (CHRS) is seeing ratings go up from a C last week to a B this week. Coherus BioSciences, Inc. focuses on developing and commercializing biosimilar products worldwide. The company also gets A’s in sales growth, earnings revisions, and earnings surprise. For more information, get Portfolio Grader’s complete analysis of CHRS stock.

CASI Pharmaceuticals Inc (CASI) gets a higher grade this week, advancing from a C last week to a B. The company also gets A’s in earnings revisions and earnings momentum. For more information, get Portfolio Grader’s complete analysis of CASI stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.